View Older Stories View More Recent Stories

May 23, 2022 07:04AM Greenwich LifeSciences (GLSI) Resumes $4.5M Share Buyback
May 23, 2022 07:00AM Greenwich LifeSciences to Resume Stock Repurchase Program
May 23, 2022 06:06AM Greenwich LifeSciences (GLSI) Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
May 23, 2022 06:00AM Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
Apr 20, 2022 06:10AM Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
Apr 19, 2022 06:21AM Greenwich LifeSciences (GLSI) Presents Phase IIb Data Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
Apr 19, 2022 06:21AM Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
Mar 3, 2022 09:19AM Greenwich LifeSciences (GLSI) Issues Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
Mar 3, 2022 09:19AM Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
Feb 3, 2022 06:00AM Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
Feb 1, 2022 06:03AM Greenwich LifeSciences (GLSI) Announces Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Feb 1, 2022 06:00AM Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Jan 24, 2022 06:01AM Greenwich LifeSciences (GLSI) Announces $10M Share Buyback, Extends Insider Lock-Up for 1 Extra Year
Jan 24, 2022 06:00AM Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
Dec 15, 2021 06:00AM Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
Dec 9, 2021 06:29AM Greenwich LifeSciences (GLSI) Reports 5 Year Data for GP2 Phase IIb Clinical Trial, Reveals Potential For New T Cell Platform Technology
Dec 9, 2021 06:29AM Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
Dec 8, 2021 07:00AM Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
Dec 7, 2021 06:34AM Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
Dec 6, 2021 07:15AM Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
Nov 18, 2021 06:00AM Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
Nov 17, 2021 06:00AM Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
Nov 11, 2021 06:00AM Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
Nov 10, 2021 07:07AM Greenwich LifeSciences (GLSI) Issues Clinical Update on Upcoming Phase III Trial, FLAMINGO-01
Nov 10, 2021 07:00AM Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Nov 9, 2021 06:00AM Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
Sep 28, 2021 06:00AM Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
Sep 27, 2021 06:00AM Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
Sep 23, 2021 06:00AM Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
Sep 13, 2021 06:00AM Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Sep 9, 2021 06:00AM Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
Sep 7, 2021 06:00AM Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
Jun 8, 2021 06:00AM Greenwich LifeSciences Set to Join Russell 2000® Index
Jun 7, 2021 06:32AM Greenwich LifeSciences (GLSI) Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021
Jun 7, 2021 06:30AM Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
Apr 19, 2021 10:30AM Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization
Apr 14, 2021 06:01AM Greenwich LifeSciences (GLSI) Highlights Update of GP2 Phase III Clinical Trial Design
Apr 14, 2021 06:00AM Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
Apr 12, 2021 06:14AM Greenwich LifeSciences (GLSI) Reports Poster Publication of Final 5-Yr GP2 Phase IIb Clinical Trial Immune Response Data
Apr 12, 2021 05:52AM REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival
Apr 10, 2021 04:13PM Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recu
Apr 9, 2021 06:12AM Greenwich LifeSciences (GLSI) Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
Apr 9, 2021 05:00AM Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
Mar 23, 2021 06:00AM Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference
Mar 11, 2021 06:00AM Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
Mar 10, 2021 07:59PM Greenwich LifeSciences CEO to be Interviewed Live on Benzinga’s Power Hour
Mar 8, 2021 06:00AM Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
Mar 2, 2021 06:00AM Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences
Dec 11, 2020 06:36AM Greenwich LifeSciences (GLSI) Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer
Dec 11, 2020 06:00AM Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer
View More Recent Stories View Older Stories